AS01E adjuvant system (AS01E)

Molecular Classification

Liposomal adjuvant, Immunostimulant combination (contains monophosphoryl lipid A, MPLA, and QS-21), Delivery system (liposome platform)

Other Names

AS01E, GSK proprietary liposomal adjuvant system, AS01 family, Adjuvant System 01E

Disease Roles

Infection (supporting vaccines against Herpes zoster, malaria, respiratory syncytial virus, tuberculosis)

AS01E adjuvant system Overview

The AS01E adjuvant system is a liposomal vaccine adjuvant formulation developed by GlaxoSmithKline, comprising monophosphoryl lipid A (a detoxified TLR4 agonist derived from Salmonella) and QS-21 (a saponin purified from Quillaja saponaria) in cholesterol-containing liposomes. AS01E boosts immune responses by activating innate immune sensors (TLR4 and NLRP3 inflammasome pathways), inducing production of proinflammatory cytokines and enhancing antigen presentation, ultimately resulting in robust T cell and antibody responses. It is incorporated in several licensed vaccines, including Shingrix, RTS,S/AS01E, AREXVY, and investigational vaccines like M72/AS01E for tuberculosis. AS01E itself is not a molecular target but a platform acting upon multiple molecular and cellular targets within the immune system, making "Immune system activation via AS01E adjuvant" a mechanism or process rather than a strict pharmacological target.

Mechanism of Action

Synergistic activation of innate immunity by MPL (TLR4 agonist) and QS-21 (saponin, NLRP3/caspase-1 pathway) Stimulation of antigen-presenting cells Induction of proinflammatory cytokines (IL-1β, IL-18, IFN-γ) Promotion of adaptive immunity (enhanced antibody and T cell responses)

Biological Functions

Immune response enhancement

Innate immune activation (via TLR4)

Antigen presentation facilitation

Induction of proinflammatory cytokines (IL-1β, IL-18)

Promotion of Th1-type responses and cytotoxic T lymphocyte (CTL) generation

Disease Associations

Infection (supporting vaccines against Herpes zoster, malaria, respiratory syncytial virus, tuberculosis)

Safety Considerations

Acceptable safety profile in licensed vaccines; key challenges include minimizing reactogenicity from immune activation (e.g., injection-site reactions, fever, etc.)

Interacting Drugs

Shingrix (herpes zoster)

RTS,S/AS01E (malaria)

AREXVY (RSV)

M72/AS01E (tuberculosis)

Associated Biomarkers

Biomarker
Proinflammatory cytokines: IL-1β, IL-18, IFN-γ
Immune gene expression signature post-vaccination